Mind Medicine (MindMed) Inc (MNMD)

[PyroStocks]

November 2022 Investor Deck

---

FILE URL: https://mindmed.co/wp-content/uploads/2022/11/MindMed_InvestorPresentation_Nov.-2022_FINAL.pdf

---

TEXT TRANSCRIPT BEGIN

Business Highlights

Our mission is to deliver on the therapeutic potential of psychedelics
and other nouel targets to treat brain health disorders

/ /

• A leader in developing psychedelic product candidates to treat brain health di/orders
• Diversified pipeline of clinical programs targeting significant unmet medical needs
• IP and R&D strategies intended to maximize market exclusivity and protection
• Leveraging decades of research on clinical and preclinical potential of product candidates
• Expertise in drug and digital medicine development and commercialization
• Expected cash runway through key clinical readouts and into first half of 2025
~i MindMed Corporate Overview I November 2022


Our Leadership Team

Our management has decades of successful leadership, product development, and commercialization in pharma and biopharma


Robert Barrow Miri Halperin Wernli, PhD Daniel Karlin, MD, MA Schond Greenway, MBA Francois Lilienthal, MD, MBA Carrie Liao, CPA

Chief Executive Officer and Executive President Chief Medical Officer Chief Financ,al Officer Chief Commercial Officer Corporate Controller & Principal
Board Director Accounting Officer

Usona ZillI Health Mode avalo

(•MSD 0 MERCI< @Q~},S,,cals

In•, • 1 , ~

THERAPEUTICS

Pfizer

mannkind

@ CJP.folozyme ~~

OLJ\T:'.:C


Gen Mark ox·


~lhBristol Myers Squibb

Tufts

u l\'FRSIT)

BARCLAYS

•

~~-~

Morgan Stanley

~i MindMed Corporate Overview I November 2022


Our R&D Leadership Team

Our R&D team has decades of successful leadership, product development, and commercialization in pharma and biopharma


Peter Mack, PhD

VP, Pharmaceutical Development

AstraZeneca

0 Liquidia

Bridget Walton, MS, RAC

VP, Global Regulatory Affairs

~r~

~~sunovion

f NOVARTIS


Wyeth

Robert Silva, PhD Carole Abel, MBA

VP, Heod of Development VP, Programs & Portfolio Office (PPO)

zo NIX

ACTELION


~ Schering-Plough

~i MindMed Corporate Overview I November 2022


There is an Urgent Need for Better Treatments

Substantial opportunities exist to advance novel treatments for a wide range of brain health disorders

1 in 5 U.S. Adults has a Diagnosable

1

Mental Health Disorder

1. NIMH 2020; Mental Illness.
2. Bondelow 2015; Dialogues Clin. Neurosci; 17(3).
3. Kessler RC, Adler L, Barkley R, et al. 2005; Am J Psychiatry. 163(4).
4. Leigh & Du 2015; J. Autism Dev. Disord.; 45(12).
~i MindMed

>


~

X

UJ 21°/o

z

<l'.

:I:
0

0
<l'. 4.4°/o

V)

0 $461B

<l'.

1-year prevalence of anxiety
disorders in the US2

estimated prevalence rate of
ADHD among all US adults

3

economic cost of ASD in the
US predicted by 2025 4

Corporate Overview I November 2022


Advancing Multiple Generations of Drug Candidates

Our strategy is to deliver on well-characterized psychedelic candidates and next-generation candidates with enhanced drug profiles

CONCEPT MINDMED PRODUCT CANDIDATES PIPELINE EXPANSION OPPORTUNITIES

0

• Preliminary evidence of efficacy 1 • Expanded clinical indications
CLASSIC

• Well-characterized pharmacology • Psychedelics with distinct PK/PD
PSYCHEDELICS

MM-120 ~ Universitiitsspital

• Accelerated development potential ~1-1
.,o Mescaline / Basel

LSDD-tcrtrote


• Advanced drug delivery
• Enhanced pharmacology
2ND GENERATION/

• Novel treatment models
Potential to overcome safety liabilities

OPTIMIZED

MM-402

• Increased IP potential • Novel treatment regimen
Rf-)·MDMA

• Novel tryptamines
• Analogues of classic psychedelics
3RD GENERATION/

• Require full development program • Novel phenethylamines
NCEs

• Strongest IP potential MM-110" • Non-hallucinogenic analogues
zc lunicant HCJ

'Continued deuelopment of MM-110 is currently subject to the Company obtaining non-dilutiue sourcesof capital and/or collaboration partners.

1. Gasser 2014; J. Nerv. Ment. Dis.; 202(7).
IP: intellectual property; DMT: N,N-dimethyltryptamine; MDMA: 3,4-methylenediaxymethamphetamine; NCE: new chemical entity; PD: pharmacodynamics; PK: pharmacokinetics
~i MindMed Corporate Overview I November 2022


Research & Development Pipeline

Our pipeline diversification offers potential opportunities across therapeutic areas and mechanisms of action

PRODUCT CANDIDATE INDICATION PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION

PSYCHIATRY

MM-120 /LSDD-tartrate) Generalized Anxiety Disorder
ADHD
MM-402 (R(-)-MDMA) Autism Spectrum Disorder


SUBSTANCE USE DISORDERS
MM-110 (zolunicant HCIJ' Opioid Withdrawal


DISCOVERY & EARLY DEVELOPMENT
Novel tryptamines undisclosed
Novel phenethylamines undisclosed
Advanced drug delivery undisclosed


INVESTIGATOR-INITIATED TRIALS ..

Lysergic Acid Diethylamide (LSD) Major Depressive Disorder
Lysergic Acid Diethylamide (LSD) Cluster Headache
PK/PD of MOMA enantiomers Healthy Subjects

• Continued deue/opment of MM-110 is currently subject to the Company obtaining non-dilutiue sources of capital and/or collaboration partners.
•• Full trio/ details and clinical trials.gou links auailab/e at mindmed.co/clinical-digital-trials/
ADHD: Attention-Deficit/Hyperactivity Disorder; LSD: lysergic acid diethylamide; MOMA: 3,4-methylenedioxymethamphetamine

~i MindMed Corporate Overview I November 2022


Advancing the Field with Strong IP & Strategic Competitive Moats
MindMed seeks to protect innovation and market potential through intellectual property-oriented R&D strategies
Proactive Lifecycle
Management
Opportunities
for Innovation
& Strong IP
Market Protection
Strategies
Strategic Life Cycle Management & Late-Stage IP
Development Can Significantly Extend Market Protection
FDA-granted ~~E 1111111 exclus1v1ty
Extended market protection 111111111111111 with superior LCM*
IP-Driven
R&D Direction
Marketexclusivitybased 11111111111111111111 on late-development IP*
5
•For illustrotive purposes only
R&D: Reseorch & Development; LCM: Life Cycle Monogement; NCE: New Chemical Entity
~i MindMed
10
POTENTIAL YEARS OF MARKET
PROTECTION
15
Corporate Overview I November 2022
20
9

GAD Readout
Late 2023 I Phase 2b
ADHD Readout
Late 2023 I Phase 2a
GAD Readout
Late 2023 I Phase 2b
ADHD Readout
Late 2023 I Phase 2a
~i MindMed Corporate Overview I November 2022


Lead Candidate with Evidence Across Multiple Therapeutic Areas

Extensive evidence of clinical benefit and mechanistic rationale in psychiatry

SAFETY &
PHARMACOLOGY
1. Gasser 2014; J. Nerv. Ment. Dis.; 202(7).
2. Fuentes 2020; Front Psychiatry; 10:943.
~i MindMed


1

and other brain disorders

Broad Applicability

preliminary signs of efficacy
across multiple diagnoses 1

Rapid & Sustained

benefit observed after
acute dosing 1

10,000+

patients treated in
clinical trials 1

Long-Term Value

through multi-pronged life
cycle management

3x Effect Size

compared to leading
anxiety treatments 2

Well-Characterized

tolerability, pharmacokinetics
and pharmacodynamics

Corporate Overview I November 2022


Emerging Treatment Paradigm for Brain Health Disorders

1

MM-120 is a potent serotonin agonist with potential applications to a broad range of brain health disorders


Global Brain Connectivity


Psychedelic

Placebo


drug

Entropic brain activity

Placebo Psychedelic Drug
(Low Entropy) (High Entropy)

~~~~ ~

Increased single neuron excitability

Layer V
pyramidal
neuron

2.0 1.5 1.0 0.5 0.0

Enrichment of 5-HT2A Expression

...J5 mV
2 min
1. Nutt 2020. Cell; 181(1).

~i MindMed Corporate Overview I November 2022


Legacy of LSD Clinical Research in Psychiatric Disorders

Building on decades of clinical research on LSD in anxiety and depression

STUDIES INDICATION(S) SAMPLE SIZE KEY FINDINGS

21 STUDIES Anxiety, depression &

512 patients Up to 95% reduction in symptoms

PRIOR TO 19741 neurotic illnesses

Anxiety in terminal Effect size of 1.1 with durable

GASSER 2014 2 12 patients

illness reduction in anxiety at 1 year

Rapid and durable reduction in
symptoms post-treatment. Clinical

UH B's LSD-ASSIST 3 Anxiety 42 patients

response in 65% of LSD patients
vs. 9% in placebo

1. Rucker 2016. J. Psychopharmacol; 30(12).
2. Gasser 2014. J. Nerv. Ment. Dis.; 202(7).
3. Holze, Gasser et. al 2022. Biological Psychiatry.
~1i)MindMed

Corporate Overview I November 2022


Evidence in Anxiety Disorders

Results from UHB's LSD-Assist study support MindMed's clinical development of MM-120 for GAD

Reduction in Anxiety Symptoms (STAI-G)

Rapid, durable and significant anxiolytic effects 1

20

• Reduction in anxiety and depression symptoms; durable
10

at 16 weeks post-treatment vs. placebo (p<0.007}

• Clinical response (::::30% reduction} observed in 65% of 0
(.'.)

I

LSD group vs 9% of placebo group (p<0.003}


• Positive correlation between acute positive effects or
~
V)
<J
-10
* *
mystical experiences and clinical outcomes
-20
• Well-tolerated at 200 µg: 1 serious adverse event (acute
transient anxiety and delusions} and no other adverse -30
events attributed to treatment
? Placebo (n=22)
• No instances of suicidal ideation with intent attributed to --LSD
(n:20) 0 (2) 5 (B) 10 16 24
treatment Source: [1]
Time (Weeks) •• p < 0 01
"'"p<0001

1. Holze, Gasser et. al 2022. Biological Psychiatry.
STAI-G: State-Trait Anxiety Inventory; µg: microgram
~1i)MindMed Corporate Overview I November 2022


MM-120 I Phase 2b Generalized Anxiety Disorder (GAD)

Study design seeks to evaluate dose-responsive effects and identify optimal dose for pivotal clinical trials

PSYCHIATRY MM-120 /LSD D-tortrate}

Indication: GAD

FIIKH!li

200 participants total (n=40/arm) I

Week

Prep Follow-Up

L Secondary Endpoints
HAM-A

Placebo


Randomize Primary Endpoint

HAM-A

Source: Mind Med internol study documents
µg: microgrom; HAM-A: Hamilton Anxiety Rating Scale; MADRS: Montgomery-Asberg Depression Roting Scale; CGI-S: Clinicol Globol Impression -Severity; PGI-S: Pot,ent Global
Impression -Severity; SOS: Sheehan Disability Scale; E0-5D-SL: EuraOal-5 Dimension; PSOI: Pittsburgh Sleep Quality Index; ASEX: Arizona Sexual Experiences Scale

~1i)MindMed

Study MMED008 I MM-120 for GAD

A Phase 2b Dose Optimization
Study of a Single Dose of MM-120
in Generalized Anxiety Disorder

KEY ENTRY CRITERIA

• Men and Women
• Ages 18-74
• Diagnosis of GAD
• HAM-A 2'.20
ADDITIONAL ENDPOINTS

• MADRS • EQ-SD-SL
• CGI-S / I • PSOI
• PGI-S / C • ASEX
• SDS
Corporate Overview I November 2022


Potential MM-120 Clinical Care Model

Advancing a delivery model that seeks to optimize outcomes and scalability

Pre-Treatment


• Patient education, engagement, preparation • Continuous monitoring by qualified session monitors • Follow-up psychosocial support
• Eligibility evaluation • Non-directive psychosocial support • Continuation of standard psychiatric care
• Care coordination with existing clinical team • Accompanied discharge when release criteria met • Remote monitoring for re-treatment needs
~'§ MindMed Corporate Overview I November 2022


MM-120 I Phase 2a Attention-Deficit Hyperactivity Disorder (ADHD)

Proof of concept study design seeks to explore potential clinical response in ADHD

PSYCHIATRY MM-120 /LSD D-tortrate} Indication: ADHD

FIHM!#I

52 participants total (n=26/arm)

Week

Secondary Endpoint

AISRS

MM-120 20 µg q3d

Placebo q3d

Randomize

Prep Dosing Follow-Up
Primary Endpoint

AISRS


Source: Mind Med internol study documents
AISRS: Adult ADHD lnvestigotor Symptom Rating Scale; ASRS: Adult ADHD Self-Report Scale; CAARS: Conners' Adult ADHD Rating Scoles; CGI-S: Clinical Global Impression

~i MindMed

Study MMED007 I MM-120 for ADHD

I

A Phase 2a Proof of Concept Study
of Repeated Low Doses of MM-120
for the Treatment of ADHD in Adults

KEY ENTRY CRITERIA

• Men and Women
• Ages 18-65
• Diagnosis of ADHD
• AISRS?: 26
• CGI-S ?: 4
ADDITIONAL ENDPOINTS

• AISRS
• CGI-S
• ASRS
• CAARS
• Sleep Diary
-Severity

Corporate Overview I November 2022


Potential Pathway to Commercial Success for MM-120

Our approach seeks to leverage well-established pathways to bring novel therapeutics to patients at scale

• Seek approval for drug product candidates in major markets globally
Submit Marketing
Applications • Collaborate with healthcare authorities to seek targeted labeling
• Strategic plans for long-term product life cycle management and market preservation

• Review rescheduling processes of preceding products
Rescheduling • Advance conversations with national, federal, and state authorities
• Propose rescheduling in marketing applications
• Engage payers to develop a comprehensive market access strategy
Reimbursement • Generate HEOR evidence to maximize reimbursability of drug and dosing session
• Develop provider tools to enhance reliability of reimbursement
• Employ a precedent-based development strategy that bridges the novelty
Real-World Adoptability

of the therapeutic class with the existing care delivery landscape

HEOR: health economics outcomes research

~i MindMed Corporate Overview I November 2022


Phase 1 Study Initiation
2023 I Phase 1
Phase 1 Study Initiation
2023 I Phase 1
~i MindMed Corporate Overview I November 2022


No Approved Drugs for Core Symptoms of Autism Spectrum Disorder (ASD)

Growing prevalence and impact of ASD yields an urgent need for novel therapies that target core symptoms and align with patient preferences

R(-)-MDMA Activity Aligns with Reported Needs and
Desired Benefits for Individuals with ASD


55%

41%


Reduced Reduced
Social Communication
Impairment Difficulties

Most desired
treatment benefits

% of Patients

Source: [1]

62%

Ability to
Participate

57%

Impact on
Relationships

Aspects of life most
impacted by ASD

% of Patients

1. FDA Potient Focused Drug Development workshop on Autism Spectrum Disorder (2017)
~'§ MindMed Corporate Overview I November 2022


Preclinical Data Indicate Potential Enhanced Benefit/Risk Profile

Preclinical data suggest the R-enantiomer of MDMA has prosocial effects with reduced stimulant activity

Translational preclinical data suggest that

R(-)-MDMA Maintains Prosocial Effects with

R(-)-MDMA may have:

Reduced Stimulant Activity

• Strong prosocial effects ] 200%
C
0

u

vi

• Less stimulant activity compared to MDMA ::,
~

C)

C

0

• Plan to develop standard, at-home dose regimen u -C 100%
-I

Source: (1)(2) Source: (2)
R R/S
Social
Interaction
s R R/S
Locomotor
Activity
s
1. Pitts 2018; Psychophormocology;
2. Curry 2018; Neurophormocology;
~i MindMed
235.
128.
Corporate Overview I November 2022 21


Clinical Data Support Opportunity for MDMA in ASD

Pilot clinical trial results of MDMA demonstrate acute and durable positive effects on social functioning in ASD population 1

MM-402 or R(-)-MDMA is a pharmaceutically

MDMA Reduces Social Anxiety in ASD

optimized enantiomer of MDMA

60%

:JI

"ti

.><

• Potential first-in-class therapy for core symptoms <(
C
0 40%

0

ofASD ·;:;

V)

.s


20%

• Pilot clinical data suggest racemic MDMA could
enhance social functioning

I


• Pharmacological
desired treatment
profile aligns
benefits
with patientSource:
[1)
Placebo MDMA
1 month
Placebo MDMA
6 months
1. Danforth 2018; Psychophormocology; 235.
MDMA: 3,4-methylenedioxymethomphetomine;
~'§ MindMed
ASD: Autism Spectrum Disorder
Corporate Overview I November 2022 22


~i MindMed Corporate Overview I November 2022


Novel Mechanism to Address a Critical Gap in OUD Treatment

Mechanism of action supports approach to address symptoms of opioid withdrawal and facilitate initiation of OUD treatment

Opioid Initiation Opioid Use Disorder (OUD) MM-110-facilitated Medication Assisted Therapies (MAT)
Superuised Withdrawal


A

Dopamine regulation may
facilitate completion of
detoxification & reduce cravings

Start MM-110 Induction to MAT

~i MindMed Corporate Overview I November 2022


Strong Preclinical Effect Shown on Key Translational Outcomes

A single dose of MM-110 mitigated withdrawal symptoms and opioid self-administration in preclinical models1•2

Reduction in Translational Markers of Opioid Withdrawal* Reduction in Translational Markers of OUD

30

25

(I)

....

0

u

V)--.

20

E gi

o·


........

o.2

E ....

:::no 15

~6

0-C

3't

e~ 10

-a~

..c:

....

~

5

0


125

100

(I)

.s

75

Qi

V)

0

c:o

4-.

0

(I)

0-, 50

0

....

I::

(I)

....

(I) 25

0

I Q
u

Water

•

t • •
Control 10 20 40 Morphine 0 10 20 30 40
MM-110dose (mg/kg) ----MM-110dose (mg/kg)

Source: [1) Source: [2]

1. Rho & Glick 1998; NeuroReport; 9.
2. Maisonneuve & Glick 2003; Pharmacol Biochem Behav; 7S.
'MM-110 was observed to attenuate 5 of 7 signs of withdrawal; only 1 of the 7 is shown on this slide.
~i MindMed Corporate Overview I November 2022


Phase 1 Study Results -Key Takeaways

Results of Phase 1 clinical trial demonstrate tolerability and support progression of MM-110

Phase 1 study results support progression of MM-110 (zolunicant) *

• Results from Phase 1 clinical trial demonstrate tolerability and support
progression of MM-110
• Linear PK maintained across the tested doses and frequencies
• Clinical effects align with potent CNS engagement
• 00D regimen aligns with preclinical evidence & offers potential to be a more
suitable regimen in opioid withdrawal
• Continued deuelopment of MM-110 is currently subject to the Company obtaining non-dilutiue sources of capital and/or collaboration partners.
PK: Pharmacokinetics; CNS: Central Nervous System; 00D: Latin for "every other day• (dosing regimen)
~1i)MindMed Corporate Overview I November 2022


~i MindMed Corporate Overview I November 2022


External Collaborations Aim to Accelerate Discovery & Development

Leveraging key partnerships and collaborations with intent to accelerate drug discovery and de-risk clinical development

Universitatsspital

MindShift ~1-1

; Basel

Compounds

NEW CHEMICAL ENTITY DISCOVERY ENGINE ADVANCED DRUG DELIVERY EFFICIENT CLINICAL PROVING GROUND

DISCOVERY &
LEAD OPTIMIZATION


••••?
? • ......
NOVEL DOSAGE AND DELIVERY FORMS RAPID DATA GENERATION &
TO ENABLE ENHANCED DELIVERY CLINICAL CONCEPT TESTING

~WMindMed Corporate Overview I November 2022


Exclusive Collaboration with Leading Researchers

MindMed's exclusive collaboration with the Liechti Lab at UHB enables efficient evidence generation to support R&D strategy


+

~1-1

Universitatsspital/ Basel

LSD for Anxiety

LSD for MDD

LSD for Cluster Headache


R-MDMA

MDMA analogues

Mescaline

DMT

Potential Strategic Value

• Rapid transition to
clinical evidence
generation
• Increase confidence in
clinical indications
• Efficient exploration of
PK/PD and dose
optimization
~'§ MindMed Corporate Overview I November 2022


~i MindMed Corporate Overview I November 2022


Digital Unlocks Potential Opportunities Throughout the Product Lifecycle

Generating data, insights, models, and tools from early development through market management

Preclinical Research IND & Phases 1 -3 Drug Launch Enhancement and Lifecycle Management
--~()t------------•t----------------•----------


• Deep Digital Diagnoses • Decision Support • Surveillance & Registries • Drug-Device Combinations
• Decentralized Trials • Predictive Intervention • Remote Management • Lifecycle Enhancement
• Advanced Analytics • Patient Engagement • HEOR • Efficient Phase 4 Research
HEOR: health economics and outcomes research

~i MindMed Corporate Overview I November 2022


Digital to Complement Drug Delivery Through the Patient Journey

Designing and developing a scalable delivery platform to enable adoption leveraging the existing treatment ecosystem

Pre-Treatment


• Patient education, engagement, preparation • In-session monitoring • Real world monitoring of trends
• Deep digital diagnosis • Clinician decision support • Engagement in health maintenance
• Support for treatment selection • Predictive models that link • Al models to inform psychotherapies
interventions and outcomes
SetfAeport
o I
VIIMO Olory Joumal
.........
= e o-...... --
~~ MindMed Corporate Overview I November 2022


Digital Enables Alignment of Incentives for Broad Market Access

Complementary digital medicine products and studies for improved brain health outcomes

1 Measure, diagnose & engage

2 Quality care & documentation

J Clinical decision support

4 Patient trend prediction

5 Maximize reimbursement

MindMed
Performance,
Outcome,
Trends
Sites of Care
Payers


0

Connect C,

Community Support

Anxi•ty

Social Anxiety Depression

•

~1i)MindMed Corporate Overview I November 2022


Digital Pipeline Progression Aligns with Drug Development

Executing across product categories with strong technical development and clinical research

TECHNOLOGY CANDIDATE


DISCOVERY & REAL-WORLD DATA

MINIMUM VIABLE PRODUCT &
CLINICAL DATA COLLECTION

STUDY USE, ALGORITHM DEVELOPMENT
&PRODUCT ENHANCEMENT

VALIDATION & FDA CLEARANCE

COMMERCIAL LAUNCH

Anxiety & Affective Disorders Transdiagnostic
lntrasession SaMD Component #2 Decision Support Platform

In Development In Development
-Concept development -Concept development

Anxiety Disorders

ADDAPT

In Beta Study Use
-Lorge decentralized observotionol study


P. rting System
WINSANTOK

-Next generation system -Clinical doto collection

•

Anxiety & Affective Disorders Transdiagnostic
MSMS -Platform & SoMD #1 QPEPS

In Study Use In Study Use
-Clinical data collection -Clinical dote collection

• OPEPS: Quantifying the Processes and Events of Psychotherapy at Scale
• ADDAPT: Anxiety Digital Diagnoses for Precision psychiatry
• MSMS: MindMed Session Monitoring System
• SaMD: Software-as-Medical-Device
~1i)MindMed Corporate Overview I November 2022


Business Highlights

• A leader in developing psychedelic product candidates to treat brain health disorders
• Diversified pipeline of clinical programs targeting significant unmet medical needs
• IP and R&D strategies intended to maximize market exclusivity and protection ~.,.,~-~-~~
• Leveraging decades of research on clinical and preclinical potential of product candidates 'l1~
• Expertise in drug and digital medicine development and commercialization
• Expected cash runway through key clinical readouts and into first half of 2025
• MM-120 (LSD D-tartrate) for the treatment of GAD and ADHD
• Phase 2b dose-optimization study ongoing for the treatment of GAD; topline results expected in late 2023
• Phase 2a study ongoing for the treatment of ADHD; topline results expected in late 2023
• MM-402 or R(-)-MDMA for the treatment of core symptoms of ASD
• IND-enabling studies ongoing; initiation of a Phase 1 clinical trial is planned in 2023
• Phase 1 pharmacokinetic/pharmacodynamic (UHB) investigator-initiated trial of R-, S-and R/S-MDMA in healthy volunteers ongoing
~i MindMed Corporate Overview I November 2022


MindMed

~i MindMed Corporate Overview I November 2022